Duleek Ranatunga

Duleek Ranatunga is an innovative leader in computational biology and oncology. He is the Founder and CEO of Pear Bio, a VC-backed company leveraging organ-on-a-chip and computer vision technology to simulate and analyze the tumor microenvironment. Since January 2019, he has been spearheading efforts to enhance drug development for pharma companies and assist clinicians in selecting effective cancer treatments, with a focus on solid tumors like triple-negative breast cancer.

In addition to his role at Pear Bio, Duleek writes about cancer research on his Medium blog, "Why there’s not a single cure for cancer," where he has been active since February 2019. His entrepreneurial journey also includes a stint as Entrepreneur In Residence at Merck Group from January to May 2019, and at Singularity University in early 2017, where he honed his business and entrepreneurship skills.

Duleek's experience extends to being a Growth Manager at Clearco in 2018 and co-founding Ourotech, a CRO for oncology drug development, from 2017 to 2018. His early career involved research in tissue engineering and nanomaterial-based water treatment at the University of Waterloo, showcasing his strong background in scientific research and innovation.

• Pear Bio, Founder and CEO: Jan 2019 - Present
• Why there’s not a single cure for cancer, Writer: Feb 2019 - Present
• Merck Group, Entrepreneur In Residence: Jan 2019 - May 2019
• Clearco, Growth Manager: 2018
• Ourotech, Cofounder: 2017 - 2018
• Singularity University, Entrepreneur In Residence: Jan 2017 - Apr 2017
• Stealth startup, Manager: Jan 2015 - Dec 2016
• University of Waterloo, Research Fellow: Hydrogels for Tissue Engineering: 2015
• Hydrosole, Cofounder: Aug 2014 - Dec 2014
• University of Waterloo, Researcher: Nanomaterial-based Water Treatment: 2014

‍